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Abstract
Background Secondary hyperparathyroidism increases the risk for fractures. Despite improvement in medical
therapy, surgical parathyroidectomy (PTX) often becomes necessary, but its effect on risk of fractures is not clear.
Our aim was to study the effect of parathyroidectomy on the risk of hip fractures in patients on dialysis or with a
functioning renal graft at time of parathyroidectomy.
Design In a cohort of 20,056 patients on dialysis or with functioning renal allograft, we identified 590 patients who
underwent parathyroidectomy between 1991 and 2009. Of these, 579 were matched with 1970 non-PTX patients on
age, sex, cause of renal disease and functioning renal allograft or not at the time of PTX or at the corresponding time
for non-PTX patients (t). We calculated the risk for hip fracture after PTX using crude and adjusted Cox proportional
hazards regressions, adjusting for time in renal replacement therapy before t, time with functioning renal allograft
before and after t, comorbidity at t and a hip fracture before t.
Results The adjusted hazard ratio (95% confidence interval) for hip fracture was 0.40 (0.18–0.88) for PTX patients,
compared to non-PTX patients. When analyses were performed separately for sex, only women had a lower risk of
hip fracture after PTX compared to non-PTX patients. The risk of hip fracture after PTX was similar in patients with
or without functioning renal allograft at time for PTX.
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Secondary hyperparathyroidism (sHPT) is common among
patients on chronic renal replacement therapy (RRT) [1].
SHPT increases the risk for fractures [2–5], and patients on
RRT have a higher risk of fractures than the general pop-
ulation [6]. Patients on dialysis or with a renal transplant
have different, additional risk factors for fractures than the
general population such as immobility during time spent on
dialysis, treatment with corticosteroids, abnormal levels of
PTH [7]. In sHPT, the mineral metabolism is disturbed and
levels of parathyroid hormone (PTH) are increased. This is
treated medically, but in patients with severe sHPT who
fail to respond to medical therapy, surgical removal of
parathyroid glands is required. Surgical parathyroidectomy
(PTX) reduces plasma levels of PTH calcium and phos-
phate [8, 9], but the effect of PTX on fracture risk has not
been well documented [9]. There are indications that PTX
improves bone density and bone pain [10, 11]. A previous
study found a reduction in risk of fractures [12], but
included only patients on dialysis. Patients with a renal
transplantation are an important group within the RRT
population, and the effects of PTX on fractures in these
patients are not known. Therefore, we aimed to study the
effect of PTX on the risk of hip fractures in patients on
dialysis and in patients with a functioning renal graft at
time of PTX in a nationwide, population-based cohort.
Methods
Study cohort
We performed a matched index-referent study within a
cohort consisting of all patients in the Swedish Renal
Registry (SRR) between 1 January 1991 and 31 December
2009. Registration in the SRR is mandatory for all patients
who start dialysis or receive a renal transplant in Sweden.
All dialysis- and renal transplantation units in Sweden are
affiliated with SRR, and its coverage is almost 100% [13].
In this study, RRT was defined as treatment with mainte-
nance dialysis or a having a functioning renal transplant.
Identification of PTX, comorbidity and fractures
To retrieve date of PTX and hospital discharge diagnoses,
we linked data from the Swedish Inpatient Registry to
SRR. The Swedish Inpatient Registry has a national cov-
erage of nearly 100% since 1987 and has high validity
[14, 15]. We defined PTX as total or subtotal parathy-
roidectomy. The dates of PTX were then compared with
data from the Scandinavian Quality Register for Thyroid
Parathyroid and Adrenal Surgery (SQRTPA). Since its start
in 2004, this registry collects information on all thyroid and
parathyroid surgeries in approximately 90% of all units
performing this surgery in Sweden [16]. Discharge diag-
noses were translated from ICD7-9 to ICD10 by using
conversion tables from the Swedish National Board of
Health and Welfare [17]. Diagnoses were used to create
comorbidity groups according to Charlson [18], using the
algorithm described by Quan et al [19]. ICD10 codes used
to identify hip fractures were: ‘‘S72.0, S72.1, S72.2, S72.3,
S72.4, S72.7, S72.8 and S72.9’’. To validate the diagnostic
codes, we also collected codes for surgical intervention for
hip fracture using ICD10 codes: ‘‘NFJ 09, NFJ19, NFJ29,
NFJ39, NFJ39, NFJ49, NFJ59, NFJ69, NFJ79, NFJ89 and
NFJ99’’. We chose hip fracture as our main event since it
usually leads to hospitalization and thus can be studied
through the inpatient register.
Exclusions
During the study period, there were 20,056 patients in the
SRR. Of these, we excluded 175 patients due to: PTX
before registration in SRR (n = 130), censoring (death) at
date of initiation of SRR (n = 27), errors in reporting of
patient information (n = 15) and death at date of
parathyroid surgery (n = 3).
Matching
After entry in SRR, 590 patients underwent PTX. These
patients were matched with one to five patients who had
not undergone PTX. Patients were matched using the fol-
lowing criteria: birth year (in 10 year categories), sex,
cause of renal failure in categories (autosomal dominant
polycystic kidney disease, diabetes mellitus, glomeru-
lonephritis, nephrosclerosis, pyelonephritis and other/un-
known) and if the patient had a functioning renal allograft
at the calendar date of PTX (or at the corresponding time
for non-PTX patients, t). Fracture-free survival time was
calculated by assigning both the index and referent patients
the calendar date of PTX of the index patient, hereafter
referred to as t. The matched reference patient was required
to be alive on this date and to have the same transplantation
status as the cases at the calendar date of PTX. Eleven PTX
patients could not be matched. The completed matched set
consisted of 2549 patients. The same cohort and matched
set were recently used by our group to study survival after
PTX [20].
Statistical analyses
For descriptive data, numbers and column per cent are
reported for categorical variables and means and standard
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deviations (SD) for continuous variables. We calculated
incidence rates of hip fractures in the whole cohort, as well as
for the matched set of PTX and non-PTX patients using time
from start in RRT until first hip fracture, death or end of
follow-up 31 December 2009, whichever occurred first. We
calculated incidence rates for sex, age at start of RRT (in 4
categories: \55 years, 55–65 years, 65–75 years and
[75 years) and parathyroidectomy or renal transplantation at
any time during the time of observation separately. Time to
hip fracture after PTX was calculated with the Kaplan–Meier
method, yielding survival curves. Crude and adjusted Cox
proportional hazard models were created to compare hazard
ratios with 95% confidence intervals (CI) for hip fractures
between PTX and non-PTX patients in the matched set. In the
adjusted model, we used Charlson index score at t as a con-
tinuous co-variate, accumulated time in RRT before t as a
categorical co-variate in three categories (0–2 years,
2–4 years,[4 years) using 0–2 years as reference, and hip
fracture before t as a categorical co-variate using no hip
fracture as reference. Time with a functioning graft before
twas used as a categorical co-variate in three categories (none,
1–3 years,[3 years), using none as reference. Time with a
functioning graft after twas used as a categorical co-variate in
three categories (none, 1–4 years,[4 years) using none as
reference. The time intervals differ between these variables
due to unequal distribution of patients. Cox regressions were
performed for the PTX and matched non-PTX patients, sep-
arately in men and women, separately in patients with and
without a history of hip fracture and separately in patientswith
andwithout a functioning renal allograft at the calendar date of
PTX (t).We considered results being statistically significant if
P\ 0.05. All statistical analyses were made using STATA
version 12 (StataCorp LP, College station, USA).
Results
Demographics and patient characteristics
Patient characteristics of the whole cohort and the matched
set of PTX and non-PTX patients are shown in Table 1.
Patients in the whole cohort were older at the start of RRT,
more often male, and had more often diabetes mellitus as
cause of renal failure and were less likely to have received
Table 1 Patient characteristics
Factor Whole cohort (n = 20,011) Matched PTX and non-PTX patients (n = 2549)
PTX (n = 579) Non-PTX (n = 1970)
Age (years) at start in RRT 62.8 (16.5) 50.1 (14.3) 50.4 (14.3)
Age at PTX (or corresponding date
for non-PTX patients = t)
– 54.1 (13.6) 54.0 (13.7)
Sex
Female 7131 (35.6) 297 (51.3) 975 (49.5)
Male 12,880 (64.4) 282 (48.7) 995 (50.5)
Time on RRT at PTX (t) (years) – 4.0 (3.2) 3.5 (3.4)
Cause of ESRD
ADPKD 1572 (7.9) 84 (14.5) 293 (14.9)
Diabetes mellitus 4843 (24.2) 89 (15.4) 317 (16.1)
Glomerulonephritis 3182 (15.9) 179 (30.9) 642 (32.6)
Nephrosclerosis 3651 (18.2) 57 (9.8) 175 (8.9)
Pyelonephritis 1009 (5.0) 48 (8.3) 118 (6.0)
Other and unknown 5754 (28.8) 122 (21.1) 425 (21.5)
Number of transplantations
0 14,951 (74.7) 214 (37.0) 752 (38.2)
1 4686 (23.5) 298 (51.4) 1096 (55.6)
2 347 (1.7) 58 (10.0) 114 (5.8)
3 23 (0.1) 8 (1.4) 7 (0.3)
4 4 (\0.1) 1 (0.2) 1 (0.1)
Functioning allograft at PTX (t) – 156 (27.0) 736 (37.3)
Charlson comorbidity score at PTX (t) – 1.2 (1.6) 1.4 (1.8)
Hip fracture before PTX (t) – 22 (4.0) 57 (3.0)
Mean (standard deviation), numbers (percent), PTX parathyroidectomy, RRT renal replacement therapy, ESRD end-stage renal disease, ADPKD
autosomal dominant polycystic kidney disease
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a renal transplant, compared with patients in the matched
set. PTX and non-PTX patients in the matched set were
similar to each other, both regarding matched and unmat-
ched variables, Table 1. In the matched set of PTX and
non-PTX patients, we found a total of 87 hip fractures after
t and a total of 70 surgical procedures related to hip frac-
ture after t. There were 79 patients who had suffered from
hip fracture before t, of these there were 43 female and 36
male patients. In the PTX group, 22 patients (4%) had a
prior hip fracture compared with 57 (3%) in the non-PTX
group. Median follow-up was 4 years and 7 months.
Fracture incidence
The unadjusted incidence rate for hip fractures in the total
cohort was 11.0/1000 person years [95% confidence interval
(CI) 10.3–11.8] with a total of 79,542 person years observed.
The overall unadjusted incidence rate for hip fracture is 2.0/
1000 person years in Sweden [16]. The incidence rates in the
matched set of PTX/non-PTX patients were overall lower
compared to the total cohort. Fracture incidences in the total
cohort and in the matched set of PTX and non-PTX patients
are summarized in Table 2.
Effect of PTX on risk of fracture
The results of the Kaplan Meier curves are shown in Fig. 1.
Analyses were made separately for PTX and non-PTX
patients, female and male patients, patients with a func-
tioning graft and patients on dialysis at time of PTX and for
patients with and without a prior hip fracture. The results of
the Cox proportional hazards model are shown in Table 3.
After adjusting for hip fracture before t comorbidity at t,
accumulated time on RRT before t, time with a functioning
graft before t and time with a functioning graft after t we
found a significantly lower hazard ratio (HR) of 0.40 (95%
CI 0.18–0.88) for hip fractures in PTX patients compared
with non-PTX patients. We also found an association
between time with a functioning graft after t and risk of hip
fracture. Patients with more than 3 years with a functioning
graft after t had a lower hazard ratio for hip fracture both in
the crude and adjusted analyses. Hip fracture before t had
the strongest association with hip fracture after t both in
crude and adjusted analyses with an adjusted HR of 5.05
(95% CI 1.57–16.23). Subgroup analyses with the same
Cox proportional hazards model are summarized in Fig. 2.
When performing analyses separately in men and women,
we found a strong association with PTX and lower risk of
hip fracture in women (compared to women who had not
undergone PTX) with an adjusted HR of 0.23 (95% CI
0.07–0.76). However, in male patients, there was no such
association Fig. 2.
Discussion
Patients who underwent PTX had a lower risk of hip fracture
comparedwith non-PTX patientsmatched on age, sex, cause
of renal disease and whether the patient had a functioning
renal graft at the date of PTX (or corresponding date, t, for
non-PTX patients). After adjusting for hip fracture before t,
time on RRT before t, comorbidities at t, time with a
Table 2 Incidence rate/1000 person years (95% CI) of hip fractures in Swedish patients on renal replacement therapy
Factor Whole cohort Matched PTX and non-PTX patients
PTX No PTX
n (%) Incidence rate n (%) Incidence rate n (%) Incidence rate
All 20,011 (100) 11.0 (10.3–11.8) 579 (100) 4.1 (2.7–6.2) 1970 (100) 6.1 (5.0–7.4)
Male 12,880 (64) 9.3 (8.5–10.2) 282 (49) 4.5 (2.5–7.9) 995 (51) 4.4 (3.2–6.1)
Female 7131 (36) 14.1 (12.8–15.6) 297 (51) 3.7 (2.0–7.0) 975 (49) 7.8 (6.1–10.0)
Age at start of RRT
\55 5481 (27) 3.8 (3.2–4.5) 350 (60) 3.0 (1.7–5.4) 1181 (60) 3.6 (2.6–4.8)
55–65 3788 (19) 10.0 (8.6–11.7) 139 (24) 2.6 (0.8–8.0) 499 (25) 7.9 (5.5–11.5)
65–75 5432 (27) 19.1 (17.0–21.5) 75 (13) 15.5 (7.4–32.6) 216 (11) 18.5 (12.0–28.3)
[75 5310 (27) 30.1 (26.8–33.8) 15 (3) 14.8 (2.1–105.3) 74 (4) 35.7 (19.2–66.3)
PTX 676 (4) 4.7 (3.2–6.7) – – – –
No PTX 19,335 (96) 11.6 (10.8–12.4) – – – –
No renal transplantation at any time
during observation
14,951 (75) 20.7 (19.2–22.2) 214 (37) 11.6 (7.0–19.2) 752 (38) 14.1 (10.8–18.5)
Renal transplantation during observation 5060 (25) 3.5 (3.0–4.1) 365 (63) 1.7 (0.8–3.6) 1218 (62) 3.7 (2.7–4.9)
PTX parathyroidectomy, RRT renal replacement therapy, – not applicable
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functioning graft before t and time with a functioning graft
after t the hazard ratio (95% CI) for hip fracture was 0.40
(0.18–0.88). As expected, we found a strong correlation
between prior hip fracture and new hip fracture as well as
between hip fracture and time spent with a functioning graft
after t. Other variables in the model were not associated with
hip fracture risk. In subgroup analyses for sex, we found that
the lower risk of hip fracture in PTX patients only was
observed in female patients. The reduced risk of hip fracture
in PTX patients was also observed by Rudser et al. [12] who
studied a population of patients on dialysis with no prior
fracture and found a hazard ratio of 0.68 (95%CI 0.54–0.86)
for fracture in patients treated with PTX compared with
patients with no PTX. They found no sex differences in the
risk of fracture after PTX. Ishani et al. studied 4435 patients
with chronic renal failure who underwent PTX and com-
pared one-year fracture rate before PTX with 1 year after
PTX. They found a non-significant decrease in the fracture
rate in PTX patients. However, they did not report whether
there were sex differences in fracture risk after PTX [21].
There are several potential explanations for the lower risk of
hip fracture after PTX in women compared with men in our
study. Female patients have a higher fracture risk in general
as well as in end-stage renal disease [6]. Women on dialysis
have higher levels of PTH than men [22] and are more likely
to undergo PTX [23, 24]. A more aggressive histological
pattern has been shown in female compared with male
patients undergoingPTX for sHPT [25]. Furthermore, Cheng
Fig. 1 Kaplan–Meier hip
fracture-free survival estimate
for PTX and non-PTX patients.
Time in years to first event.
Separate graphs for all patients,
female and male gender,
dialysis at time of PTX,
functioning renal transplant at
time of PTX, no hip fracture





et al. [26] found a worse bonemineral metabolism prior PTX
in women than in men. Thus, women seem to suffer from
more severe sHPT than men, which left untreated may carry
a greater risk of hip fracture. Hence, womenmight gainmore
from PTX in relation to fracture risk. When excluding
patients with a prior hip fracture, the adjusted hazard ratio for
PTX patients was non-significant compared to non-PTX
patients. This implies that patients with manifest osteo-
porosis have a greater effect of PTX. Bone disturbances in
CKD patients are complex, and many factors contribute to
increased fracture risk [27]. There are therefore many pos-
sible explanations as towhy PTXmight reduce the risk of hip
fracture. Elevated PTH is associated with increased osteo-
clastic and osteoblastic activity and high bone turnover [28]
with defects in the bone as a result. PTX reduces the level of
PTH in the majority of cases [8]. Mazzaferro et al. [29]
examinedmarkers of bone formation and degradation before
and after PTX in patients with renal failure and found
decreased markers of bone degradation and increased
markers for bone formation after PTX. By reducing PTH, the
high bone turnover state will likely be less pronounced,
which can contribute to better bone quality. Both calcium
and phosphate plasma levels drop after PTX and patients can
suffer from ‘‘hungry bone syndrome’’ caused by rapid re-
Table 3 Risk for hip fracture after parathyroidectomy (PTX) patients compared to references, Cox proportional hazards regression, HR (95%
CI)
Factor All (n = 2549)
Crude Adjusted
PTX No Ref Ref
Yes 0.61 (0.31–1.18) 0.40 (0.18–0.88)
Charlson index score 0.97 (0.80–1.18) 0.94 (0.76–1.16)
Hip fracture before t No Ref Ref
Yes 4.86 (1.74–13.59) 5.05 (1.57–16.23)
Cum. time in RRT before PTX 0–2 years Ref Ref
2–4 years 1.51 (0.69–3.30) 1.32 (0.57–3.06)
[4 years 2.33 (1.05–5.14) 2.40 (0.92–6.21)
Cum. time with graft before PTX None Ref Ref
1–3 years 3.31 (0.55–20.12) 5.28 (0.68–40.75)
[3 years 3.05 (0.44–21.13) 2.73 (0.28–26.79)
Cum. time with graft after PTX None Ref Ref
1–4 years 0.81 (0.25–2.56) 0.88 (0.26–3.04)
[4 years 0.19 (0.06–0.66) 0.19 (0.05–0.70)
RRT renal replacement therapy, t = date for PTX (or corresponding date for non-PTX patients)
Fig. 2 Forest plot of Cox proportional hazards (95% CI) over risk of hip fracture after PTX in subgroup analyses cases compared to references.
Adjusted for time in RRT before PTX/t, time with a renal transplant before PTX/t, Charlson comorbidity score at PTX/t, time with a renal
transplant after PTX/t and hip fracture before PTX/t. PTX parathyroidectomy
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uptake of minerals by the bone [30]. These changes might
have a positive effect for skeletal health which is favourable
for fracture outcome. We believe the inclusion of trans-
planted patients in the present study strengthens the validity
of the results. Transplanted patients have different risk fac-
tors for fractures, such as treatment with corticosteroids, but
we tried to take this into account by adjusting for time spent
with a functioning transplant both before and after time for
PTX (or corresponding time in controls). The unadjusted
incidence rate of a new hip fracture during the observation
period in the total cohort was 11.0/1000 person years (9.3 for
men and 14.1 for women). Prior findings byAlem et al. [6] in
an end-stage renal disease cohort in the USA found an
incidence rate of 7.45 inmen and 13.63 in womenwhich is in
line with our findings. The incidence rate was lower in the
matched set of PTX and non-PTXpatientswhich implies that
our selected study group has better bone health and might
have a better overall health compared to the overall end-stage
renal disease population. There are limitations to our study.
We did not have information on levels of PTH, calcium,
phosphate and renal function. We also lacked data on tradi-
tional risk factors for fractures such as medications, body
mass index, hormonal status and smoking. Selection bias
cannot be excluded, despite the matching procedure and
adjustment for potential confounding factors. Strengths in
this study include the truly population-based design. The
national registries contain information on virtually all RRT
patients in Sweden. This lessens the burden of bias due to
regional differences in clinical practice. The long follow-up
time includes different eras of sHPT treatment and PTX
frequency. Data from the Inpatient Registry used to define
PTX, co-variates and fracture endpoints have been shown to
be reliable [14, 15]. We believe that the fact that we exam-
ined hip fractures (that usually require hospitalization and in
most cases surgery) makes the results robust. Thus, we
conclude that parathyroidectomy was associated with a
reduced risk of hip fracture in female patients with sHPT.
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